Endoscopic Esophageal Topography (Endoflip 2.0) Versus High-resolution Manometry (HRM)

Sponsor
Ohio State University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05089929
Collaborator
(none)
55
1
30.4
1.8

Study Details

Study Description

Brief Summary

The purpose of the study is to investigate the use of FLIP topography in patients undergoing evaluation for gastroesophageal reflux disease (GERD). This device allows the clinician to measure muscle activity in the esophagus during a routine upper endoscopy. The FLIP topography will be used to help detect movement disorders in the esophagus, and to examine differences in patient satisfaction between FLIP topography and the standard of care procedure, high resolution manometry (HRM).

Condition or Disease Intervention/Treatment Phase
  • Device: Endoflip 2.0
  • Procedure: High Resolution Manometry

Detailed Description

The goal of the proposed research is to evaluate the endoscopic esophageal functional luminal imaging probe (FLIP) with topography (EndoflipĀ® 2.0, Medtronic, USA) as a pre-operative diagnostic test to rule out significant esophageal dysmotility in patients with gastroesophageal reflux disease (GERD). Currently, the gold standard for pre-operative motility assessment is high resolution manometry (HRM), a trans-nasal catheter test performed in an awake patient that can be quite uncomfortable, and some patients cannot tolerate.1 Conversely, Endoflip can provide similar data in a sedated patient at the time of upper endoscopy, limiting discomfort and streamlining workup. While Endoflip has been used as a complimentary tool for clinical decision making in major motility disorders, its evaluation as a potential stand-alone pre-operative test in the GERD population has been limited. However, if FLIP topography reliably excludes major motility disorders, patients could proceed with fundoplication without undergoing the additional burden of high resolution manometry (HRM) testing. Unfortunately, as of now, there are insufficient data available to justify a change in clinical practice. As a result, FLIP topography has remained relegated to a purely complimentary role.

To investigate this question, the investigators will perform FLIP topography (Endoflip 2.0) analysis on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD. Those patients with repetitive antegrade contractions (RACs) on FLIP topography will be classified as having normal motility, while any other pattern will be considered abnormal. All patients will additionally complete a standard pre-operative reflux evaluation including HRM, Upper GI series (UGI), 48-hour wireless pH testing, and baseline GERD quality of life surveys. The investigators will then compare the results of the FLIP topography measurements to the results of the gold standard high-resolution manometry (HRM) in terms of the ability of the FLIP topography to differentiate between normal and impaired esophageal function in GERD patients. Subjects will then be followed through their anti-reflux operations and post-operative outcomes will be tracked with standardized symptom questionnaires at 1, 2 and 6 months post-operatively to evaluate for post-operative dysphagia and quality of life.

The investigators hypothesize that FLIP topography (Endoflip 2.0) in GERD patients will reliably identify individuals with normal motility, which will predict good outcomes after anti-reflux surgery. If this proves to be the case, formal high resolution manometry (HRM) testing would not be necessary prior to proceeding with fundoplication, allowing a paradigm shift in the pre-operative workup of this large population of patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
55 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Endoscopic Esophageal Topography (Endoflip 2.0) Versus High-resolution Manometry (HRM) in Pre-operative Evaluation of GERD; a Non-inferiority Trial
Actual Study Start Date :
Mar 19, 2020
Anticipated Primary Completion Date :
Mar 30, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Endoflip 2.0

The investigators will perform FLIP topography (Endoflip 2.0) analysis on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.

Device: Endoflip 2.0
FLIP topography (Endoflip 2.0) analysis will be performed on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.

Procedure: High Resolution Manometry
All patients undergoing routine evaluation for gastroesophageal reflux disease will undergo high resolution manometry (HRM) testing.

Outcome Measures

Primary Outcome Measures

  1. Concordance between the presence of RACs versus the absence of major motility disorder [6 months]

    Evaluate the concordance between the presence of RACs on FLIP topography versus the absence of major motility disorder on HRM as defined by the Chicago classification system v3.

Secondary Outcome Measures

  1. Concordance between the presence of RACs versus distal esophageal amplitude [6 months]

    Evaluate the concordance between the presence of RACs on FLIP topography versus the finding of distal esophageal amplitude >20mmHg as a surrogate for adequate esophageal function for Nissen fundoplication.

Other Outcome Measures

  1. Evaluate patient satisfaction using study questionnaire [6 months]

    Evaluate patient satisfaction with the FLIP topography procedure compared to traditional High Resolution Manometry (HRM) testing using a patient satisfaction questionnaire.

  2. Post-Fundoplication Dysphagia [6 months]

    Assess rates of post-fundoplication dysphagia in patients with and without RACs on FLIP topography as determined by GERD-HRQL scale.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Suspected or known history of GERD

  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:
  • Previous esophageal or gastric surgery (including failed anti-reflux operation)

  • Hiatal Hernia > 5cm based on upper GI

  • Patients with a known major motility disorder (achalasia)

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Ohio State University Wexner Medical Center Columbus Ohio United States 43210

Sponsors and Collaborators

  • Ohio State University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kelly Haisley, Assistant Professor, Ohio State University
ClinicalTrials.gov Identifier:
NCT05089929
Other Study ID Numbers:
  • 2020H0057
First Posted:
Oct 22, 2021
Last Update Posted:
Oct 22, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes

Study Results

No Results Posted as of Oct 22, 2021